BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey JA. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget 2017;8:76525-57. [PMID: 29100331 DOI: 10.18632/oncotarget.20408] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Abrams SL, Lertpiriyapong K, Yang LV, Martelli AM, Cocco L, Ratti S, Falasca M, Murata RM, Rosalen PL, Lombardi P, Libra M, Candido S, Montalto G, Cervello M, Steelman LS, Mccubrey JA. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation 2018;69:16-34. [DOI: 10.1016/j.jbior.2018.06.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chappell WH, Candido S, Abrams SL, Russo S, Ove R, Martelli AM, Cocco L, Ramazzotti G, Cervello M, Montalto G, Steelman LS, Leng X, Arlinghaus RB, Libra M, Mccubrey JA. Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation 2018;69:43-62. [DOI: 10.1016/j.jbior.2018.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
3 Abrams SL, Akula SM, Martelli AM, Cocco L, Ratti S, Libra M, Candido S, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS, McCubrey JA. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Adv Biol Regul 2021;79:100780. [PMID: 33451973 DOI: 10.1016/j.jbior.2020.100780] [Reference Citation Analysis]
4 Ratti S, Ramazzotti G, Faenza I, Fiume R, Mongiorgi S, Billi AM, Mccubrey JA, Suh P, Manzoli L, Cocco L, Follo MY. Nuclear inositide signaling and cell cycle. Advances in Biological Regulation 2018;67:1-6. [DOI: 10.1016/j.jbior.2017.10.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
5 Steelman LS, Abrams SL, Ruvolo P, Ruvolo V, Cocco L, Ratti S, Martelli AM, Neri LM, Candido S, Libra M, McCubrey JA. Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. Oncotarget 2017;8:113013-33. [PMID: 29348885 DOI: 10.18632/oncotarget.22956] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
6 Candido S, Abrams SL, Steelman L, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, Suh P, Libra M, Mccubrey JA. Metformin influences drug sensitivity in pancreatic cancer cells. Advances in Biological Regulation 2018;68:13-30. [DOI: 10.1016/j.jbior.2018.02.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
7 Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, Cervello M, Rakus D, Gizak A, Lin H, Libra M, Akula SM, Mccubrey JA. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation 2019;72:22-40. [DOI: 10.1016/j.jbior.2019.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Jiang X, Li H, Fang Y, Xu C. LncRNA PVT1 contributes to invasion and doxorubicin resistance of bladder cancer cells through promoting MDM2 expression and AURKB-mediated p53 ubiquitination. Environ Toxicol 2022. [PMID: 35213076 DOI: 10.1002/tox.23501] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Akula SM, Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Cocco L, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-silva B, Matias de Alencar S, Falasca M, Montalto G, Cervello M, Notarbartolo M, Gizak A, Rakus D, Libra M, Mccubrey JA. Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Advances in Biological Regulation 2020;75:100672. [DOI: 10.1016/j.jbior.2019.100672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rusciano I, Marvi MV, Owusu Obeng E, Mongiorgi S, Ramazzotti G, Follo MY, Zoli M, Morandi L, Asioli S, Fabbri VP, McCubrey JA, Suh PG, Manzoli L, Cocco L, Ratti S. Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. Adv Biol Regul 2021;79:100771. [PMID: 33303387 DOI: 10.1016/j.jbior.2020.100771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Jin J, Guo Q, Xie J, Jin D, Zhu Y. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer. Pathol Oncol Res 2019;25:769-75. [PMID: 30706361 DOI: 10.1007/s12253-019-00592-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Mccubrey JA, Abrams SL, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS. Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells—Power of nutraceuticals. Advances in Biological Regulation 2018;67:190-211. [DOI: 10.1016/j.jbior.2017.09.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
13 Bertacchini J, Frasson C, Chiarini F, D'Avella D, Accordi B, Anselmi L, Barozzi P, Forghieri F, Luppi M, Martelli AM, Basso G, Najmaldin S, Khosravi A, Rahim F, Marmiroli S. Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells. Adv Biol Regul 2018;68:2-9. [PMID: 29576448 DOI: 10.1016/j.jbior.2018.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]